Literature DB >> 19197249

Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain.

Grazia Tripodi1, Lorena Citterio, Tatiana Kouznetsova, Chiara Lanzani, Monica Florio, Rossana Modica, Elisabetta Messaggio, John M Hamlyn, Laura Zagato, Giuseppe Bianchi, Jan A Staessen, Paolo Manunta.   

Abstract

BACKGROUND: Endogenous ouabain (EO) has been linked with long-term changes in sodium balance and cardiovascular structure and function. The biosynthesis of EO involves, cholesterol side-chain cleavage (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (HSD3B) with sequential metabolism of pregnenolone and progesterone. Furthermore, the renal excretion of cardiac glycosides is mediated by the organic anion transporter (SLCO4C1) at the basolateral membrane and the P-glycoprotein (PGP) (encoded by MDR1) at the apical membrane of the nephron.
METHODS: Average 24-h ambulatory blood pressures were recorded in 729 untreated essential hypertensives. Aldosterone (Aldo), EO, urinary Na+, and K+ excretions were determined. Single-nucleotide polymorphism (SNP) and haplotype-based association study was performed with a total of 26 informative SNPs.
RESULTS: Plasma EO was significantly directly related to both day (r = 0.131, P < 0.01) and nighttime diastolic blood pressure (DBP) (r = 0.143, P < 0.01), and remained significantly related after correction for confounders (sex, body mass index, age). Genotype analysis for EO levels and daytime DBP gave significant results for CYP11A1 rs11638442 and MDR1 rs1045642 (T/C Ile1145) in which the minor allele tracked with higher EO levels (T/T 210.3 (147-272) vs. C/C 270.7 (193-366) pmol/l, P < 0.001). Association was found between HSD3B1 polymorphisms and/or haplotypes with blood pressure (systolic blood pressure (SBP) 140.3 (11.7) vs. 143.8 (11.2) mm Hg, P < 0.01) and plasma Aldo (P < 0.05). Haplotype-based analyses support the data of SNP analysis.
CONCLUSIONS: Among patients with essential hypertension, cholesterol side-chain cleavage and MDR1 loci are related to circulating EO and DBP, most likely by influencing EO synthesis and transmembrane transport, respectively. In contrast, variants in HSD3B1 are related with SBP probably via Aldo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197249      PMCID: PMC3518306          DOI: 10.1038/ajh.2009.3

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  37 in total

Review 1.  Betting odds and genetic associations.

Authors:  Duncan C Thomas; David G Clayton
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

2.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.

Authors:  Dale R Nyholt
Journal:  Am J Hum Genet       Date:  2004-03-02       Impact factor: 11.025

3.  Structural and functional analysis of the mouse mdr1b gene promoter.

Authors:  D Cohen; R L Piekarz; S I Hsu; R A DePinho; N Carrasco; S B Horwitz
Journal:  J Biol Chem       Date:  1991-02-05       Impact factor: 5.157

4.  Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.

Authors:  Andreas Johne; Karla Köpke; Thomas Gerloff; Ingrid Mai; Stephan Rietbrock; Christian Meisel; Sven Hoffmeyer; Reinhold Kerb; Martin F Fromm; Ulrich Brinkmann; Michel Eichelbaum; Jürgen Brockmöller; Ingolf Cascorbi; Ivar Roots
Journal:  Clin Pharmacol Ther       Date:  2002-11       Impact factor: 6.875

5.  ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder.

Authors:  Marianne B Müller; Martin E Keck; Elisabeth B Binder; Adelheid E Kresse; Thomas P Hagemeyer; Rainer Landgraf; Florian Holsboer; Manfred Uhr
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

6.  Salt, endogenous ouabain and blood pressure interactions in the general population.

Authors:  Ji-Guang Wang; Jan A Staessen; Elisabetta Messaggio; Tim Nawrot; Robert Fagard; John M Hamlyn; Giuseppe Bianchi; Paolo Manunta
Journal:  J Hypertens       Date:  2003-08       Impact factor: 4.844

7.  Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension.

Authors:  Helen J L Speirs; Ksenia Katyk; Natasha N Kumar; Adam V Benjafield; William Y S Wang; Brian J Morris
Journal:  J Hypertens       Date:  2004-05       Impact factor: 4.844

8.  Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.

Authors:  Tsuyoshi Mikkaichi; Takehiro Suzuki; Tohru Onogawa; Masayuki Tanemoto; Hiroya Mizutamari; Masahiro Okada; Tatsuji Chaki; Satohiro Masuda; Taro Tokui; Nobuaki Eto; Michiaki Abe; Fumitoshi Satoh; Michiaki Unno; Takanori Hishinuma; Ken-Ichi Inui; Sadayoshi Ito; Junichi Goto; Takaaki Abe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

9.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.

Authors:  I A de Lannoy; M Silverman
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

10.  Relationships among endogenous ouabain, alpha-adducin polymorphisms and renal sodium handling in primary hypertension.

Authors:  Paolo Manunta; Marc Maillard; Cristina Tantardini; Marco Simonini; Chiara Lanzani; Lorena Citterio; Paola Stella; Nunzia Casamassima; Michel Burnier; John M Hamlyn; Giuseppe Bianchi
Journal:  J Hypertens       Date:  2008-05       Impact factor: 4.844

View more
  20 in total

Review 1.  Endogenous ouabain: a link between sodium intake and hypertension.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 2.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Central regulation of blood pressure by the mineralocorticoid receptor.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 5.  Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?

Authors:  Elise P Gomez-Sanchez
Journal:  Trends Endocrinol Metab       Date:  2011-03-21       Impact factor: 12.015

Review 6.  Endogenous ouabain in renal Na(+) handling and related diseases.

Authors:  Paolo Manunta; Elisabetta Messaggio; Nunzia Casamassima; Guido Gatti; Simona Delli Carpini; Laura Zagato; John M Hamlyn
Journal:  Biochim Biophys Acta       Date:  2010-03-11

7.  Endogenous ouabain and the renin-angiotensin-aldosterone system: distinct effects on Na handling and blood pressure in human hypertension.

Authors:  Paolo Manunta; John M Hamlyn; Marco Simonini; Elisabetta Messaggio; Chiara Lanzani; Maria Bracale; Giuseppe Argiolas; Nunzia Casamassima; Elena Brioni; Nicola Glorioso; Giuseppe Bianchi
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

Review 8.  HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.

Authors:  Navin Sabharwal; Nima Sharifi
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

9.  Nanomolar ouabain increases NCX1 expression and enhances Ca2+ signaling in human arterial myocytes: a mechanism that links salt to increased vascular resistance?

Authors:  Cristina I Linde; Laura K Antos; Vera A Golovina; Mordecai P Blaustein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-07-27       Impact factor: 4.733

10.  Ouabain-digoxin antagonism in rat arteries and neurones.

Authors:  Hong Song; Eiji Karashima; John M Hamlyn; Mordecai P Blaustein
Journal:  J Physiol       Date:  2013-12-16       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.